Efficacy and safety of all-trans retinoic acid, decitabine combined with venetoclax for maintenance in non-transplant patients with acute myeloid leukemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400086497

Enrollment

Unknown

Registered

2024-07-03

Start date

2024-07-03

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia

Interventions

Treatment group:all-trans retinoic acid, decitabine and venetoclax

Control group:none

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Acute myeloid leukaemia =18 years of age, ECOG 0-2 score, complete remission after =6 courses of induction and consolidation chemotherapy (stratified by prognosis of the 2022 European Leukaemia Network), including the following vulnerable populations: women, ethnic minorities, persons with disabilities.

Exclusion criteria

Exclusion criteria: Candidates for allogeneic hematopoietic stem cell transplantation, acute promyelocytic leukemia, vulnerable population (pregnant women, children).

Design outcomes

Primary

Measure	Time frame
1 year recurrence-free survival;	—

Secondary

Measure	Time frame
1 year overall survival;drug safety;	—

Countries

china

Contacts

Public ContactGuangquan Zhou

The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University

guangquan_zhou@163.com+86 159 8218 3417

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026